Hemab Therapeutics Holdings Strategic Interests and Market Opportunity in VWD

The report evaluates the impact of INCY's $1.25B+ acquisition of Vega Therapeutics on Hemab Therapeutics (COAG). It highlights that COAG remains well-positioned in the VWD market due to a broader target population and a safer mechanism compared to the acquired VGA039.

Key Takeaways

• 1.The acquisition of Vega Therapeutics (VGA039) by INCY validates the VWD market, but Hemab Therapeutics (COAG) maintains a competitive advantage through a broader patient population target and a mechanism that preserves anti-thrombotic feedback.

Table of Contents

• Upcoming Events in the Next 12-18 Months
• Valuation and Risks
• Disclosure Appendix